Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F8IL10 intra-articular treatment in rheumatoid arthritis
NCT05622175Phase 1Withdrawn
- Sponsor
- Philogen
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of f8il10 in rheumatoid arthritis (RA), sponsored by Philogen. Primary endpoints: Maximum Tolerated Dose at 9 weeks and Recommended Dose at 9 weeks. Planned start Mar 2023; status: withdrawn.
02
Drugs
f8il10
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05622175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05622175.